Article citationsMore>>
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., Kamimura, M., Sakamoto, K., Yoshimi, M., Soejima, Y., Tomizawa, Y., Isa, S., Takada, M., Saka, H. and Kubo, A. (2014) Randomized Phase III Trial of Erlotinib versus Docetaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology, 32, 1902-1908.
http://dx.doi.org/10.1200/JCO.2013.52.4694
has been cited by the following article:
-
TITLE:
Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis
AUTHORS:
Takashi Yokoi, Takayasu Kurata, Yoshitaro Torii, Yuichi Katashiba, Makoto Ogata, Naoko Murakami Satsutani, Maiko Niki, Noriko Inagaki Katashiba, Kayoko Nishimura Kibata, Shosaku Nomura
KEYWORDS:
Bevacizumab beyond Disease Progression, NSCLC, Second-Line Chemotherapy, Docetaxel
JOURNAL NAME:
Advances in Lung Cancer,
Vol.4 No.1,
March
26,
2015
ABSTRACT:
Background: Bevacizumab-based chemotherapy has
been shown to extend progression-free survival (PFS) of lung cancer, but its
effect on overall survival (OS) remains unclear. However, bevacizumab beyond
disease progression (BBP) significantly improved OS in patients with metastatic
colorectal cancer. Methods: Therefore, we retrospectively analysed 22 patients
with non-small cell lung cancer (NSCLC) who were treated with docetaxel plus
BBP at the Department of Thoracic Oncology, Kansai Medical University Hirakata
Hospital, between November 2009 and March 2013. Results: The response rate was
31.8% and the disease control rate was 86.4%. The median PFS was 4.5 months
(95% confidence interval [CI], 2.5 - 8.7 months) and the median OS was 17.2
months (95% CI, 8.5 - 25.9 months). Grade 3 and 4 adverse events included
leukocytopenia (68.2%), neutropenia (77.3%), fatigue (9.1%), proteinuria
(9.1%), febrile neutropenia (4.5%), anemia (4.5%), and anorexia (4.5%).
Conclusion: Docetaxel plus BBP was found to be generally well tolerated and
effective.
Related Articles:
-
Tetsuya Kubota, Yoshio Okano, Mizu Sakai, Takashi Yamane, Naoki Shiota, Hiroshi Ohnishi, Hisanori Machida, Nobuo Hatakeyama, Eiji Takeuchi, Tomoyuki Urata, Fumitaka Ogushi, Akihito Yokoyama
-
R. Douglas Martin, Shengyu Zhang
-
Eduardo Santiesteban, Leslie Perez, Sailyn Alfonso, Elia Neninger, Soraida Acosta, Yoana Flores, Maurenis Hernandez, Carmen Viada, Robin García, Meylán Cepeda, Daymys Estevez, Yoisbel Moreno, Amparo Macías
-
Milan Rancic, Lidija Ristic, Marina Cekic, Tatjana Pejcic
-
Lucia D’Amico, Enrico Ruffini, Riccardo Ferracini, Ilaria Roato